Alector Inc (STU:0Z2)
€ 1.69 -0.07 (-3.98%) Market Cap: 167.26 Mil Enterprise Value: -238.19 Mil PE Ratio: 0 PB Ratio: 1.47 GF Score: 55/100

Alector Inc at Goldman Sachs Global Healthcare Conference Transcript

Jun 15, 2022 / 09:00PM GMT
Release Date Price: €7.9 (+3.43%)
Madhu Sudhan Kumar
Goldman Sachs Group, Inc., Research Division - Research Analyst

And thanks for joining us today, the Goldman Sachs Global Healthcare Conference. Really pleased to be joined by the team at Alector to kind of talk to the story where things are -- where things are headed. So I'd say, let me start at a very high level.How would you broadly describe Alector's approach, particularly in neurodegenerative disease, but also in oncology.

Questions & Answers

Arnon Rosenthal
Alector, Inc. - Co-Founder, CEO & Director

Sure. So as you know, that the dominant approach for treating all neurodegenerative disorders for the last few decades was to go after misfolded proteins. So there have been more than 50 clinical trials with drugs targeting the beta amyloid pathology, there have been 15 or 20 clinical trials going after the TAU pathology, there have been clinical trials going after huntingtin in Huntington's disease, [senior ALS , SNP ALS]. And so far, the majority of these trials were quite negative or marginally positive. We, 8 years ago,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot